Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Notox gets buzzed by NAD

This article was originally published in The Tan Sheet

Executive Summary

Statements that "clinical test results show that Notox...combats the effects of alcohol intoxication" should be modified, the National Advertising Division tells A.D. Pharma following a recent review. Implied and explicit claims on TV, radio, and print ads and testimonials for the Panax ginseng/citrus reticulate supplement, found during routine monitoring, are not supported by a trial in 10 male subjects, the watchdog group adds. NAD also was troubled by claims that could lead consumers to believe that "Notox allows product users to drink and drive." A.D. Pharma said it modified the television spot prior to NAD's inquiry, and plans on revising its website...

You may also be interested in...

NAD bounces Notox to FTC

Claims for A.D. Pharma's alcohol-intoxication reducer have been referred to the Federal Trade Commission after the firm failed to make a "bona fide good faith attempt to bring its advertising into compliance with NAD's recommendations," the Council of Better Business Bureaus division says in an Aug. 19 release. Notox was the subject of a NAD inquiry in the spring (1"The Tan Sheet" May 3, 2004, In Brief). At issue were claims that clinical studies indicate the Panax ginseng/citrus reticulate supplement "combats the effects of alcohol intoxication." The watchdog group notes that the television commercial NAD objected to has been permanently discontinued...

More Top-Level Pharma Changes In India, Cipla Gets CSO

Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.

India Acts To Limit Supply Disruption From Coronavirus

Indian pharmaceutical companies will soon be asked to seek a no objection certificate for the export of 12 APIs and their formulations, as the country deals with Chinese raw material supply disruptions on the back of the coronavirus crisis. However, the move is not expected to impact the export quantum for now.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts